India Pharma Outlook Team | Wednesday, 28 October 2026
Cosmetic claims are under scrutiny after India’s drug regulator cancelled the import registration of FatX Solution over its online fat-dissolving claims.
On October 26, 2026, the Central Drugs Standard Control Organization (CDSCO) announced action against the product, registered as a cosmetic product for import into India.
The regulator identified discrepancies between the claims on the importer’s website and the approved product label, noting that claims about dissolving fat cells and reducing their size fell outside the definition of cosmetics.
The development highlights why product classification, digital marketing and product labelling must remain aligned with India’s regulatory requirements.
According to the CDSCO notice, FatX Solution was registered for import under Delhi-based importer Tekno Midas Aesthetics.
Following scrutiny of the importer’s website and product particulars, the regulator found discrepancies between the marketed claims and the approved label.
The website reportedly described FatX Solution as a treatment for dissolving fat cells and reducing their size. CDSCO considered these drug-related claims incompatible with the product’s cosmetic classification.
The licensing authority issued a show-cause notice, received the importer’s response on September 1, 2026, and found it inconclusive and unsatisfactory and CDSCO cancelled the registration with effect from October 26, 2026.
The order highlights the importance of cosmetic drug approval boundaries and accurate product positioning. It does not establish that all fat-dissolving products or aesthetic treatments are prohibited.
Also Read: India's Drug Pricing Architecture: Why the Rules Keep Expanding
Section 3(aaa) of the Drugs and Cosmetics Act, 1940, defines cosmetics by reference to purposes such as cleansing, beautifying, promoting attractiveness or altering appearance. Rule 36 of the Cosmetics Rules, 2020, prohibits false or misleading cosmetic claims.
A product registered as a cosmetic cannot automatically be promoted for every biological or therapeutic effect its seller wishes to advertise.
In the FatX case, the regulator identified claims about changing fat cells as drug claims that did not fit the cosmetic definition. The issue was therefore not limited to the wording on the packaging: the online presentation also formed part of the regulatory scrutiny.
Cosmetic marketing claims should be reviewed before publication, particularly when language implies treatment or biological effects.
The FatX development offers a practical compliance lesson for cosmetic manufacturers, importers and distributors. Cosmetic import registration is not a blanket authorization to make claims beyond the product’s approved classification.
Businesses should review three areas:
The earlier cancellation involving QR 678-Neo, an anti-hair-loss product, provides a relevant comparison. In December 2025, CDSCO acted after the product was promoted online for conditions including post-chemotherapy hair loss and androgenetic alopecia.
Both cases involved discrepancies between online promotional claims and approved product particulars, although the specific claims differed.
For companies operating in India’s cosmetic and aesthetic-products markets, these regulatory actions reinforce the need to assess product classification and marketing language together. A documented review process can help identify inconsistencies before products reach consumers.
.jpg)
